Scanning chemical fingerprints to see if ordinary cell s reprogramming into stem cell is glitch-free asiaresearchnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaresearchnews.com Daily Mail and Mail on Sunday newspapers.
Induced pluripotent stem cells hold great promise for regenerative medicine
The 2012 Nobel prize-winning discovery that ordinary cells could be coaxed to revert to their earliest pluripotent stage ushered in the era of ethical stem cell research. Suddenly, scientists can have an inexhaustible supply of pluripotent stem cells the most versatile of stem cells that can become any type of cell much like how embryonic stem cells function but without the ethical troubles that hampered research in the past.
These reprogrammed cells called induced pluripotent stem cells, or iPS cells, hold great promise for regenerative medicine, where they can be used to develop tissue or organ replacement-based treatments for life-threatening diseases.
Webinar: Chernobyl at 35: Recovery lessons for radiation emergency preparedness who.int - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from who.int Daily Mail and Mail on Sunday newspapers.
Kyoto University A team of scientists led by CiRA Professor Haruhisa Inoue reports the combination of deep learning and iPS cell technology for the diagnosis of amyotrophic lateral sclerosis (ALS). For many devasting neurological diseases like Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), patients are diagnosed only after becoming symptomatic. However, the evidence of memory and muscle loss is seen only after the disease has progressed to irreversible states. Researchers are therefore exploring ways to identify patients well before they become symptomatic, which could allow for wider clinical options. “If we can catch the disease at the reversible stage, we may reverse and cancel the disease.” said CiRA Prof. Haruhisa Inoue, a specialist of ALS research using iPS cells.
Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)
- Studies Showed Statistically Significant Improvements in Survival in Subjects Treated with Leukine Starting 48 Hours After Acute, High Dose Radiation Exposure without Need for Blood Transfusions or Other Forms of Intensive Supportive Care
- Leukine Administration Starting 48, 72, 96 and 120 Hours after Lethal Radiation Exposure:
- Enhanced Recovery of Platelets, Lymphocytes, Neutrophils and Reticulocytes
- Reduced Frequency, Severity and Duration of Infection, Septicemia and Hemorrhage1
- Studies Provided the Basis for FDA Approval of Leukine for Treatment of Myelosuppression and Hematopoietic Damage and Dysfunction Resulting from ARS